Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Shenshen Lai, Rick Li, Paromita Raha, Yuxiang Hu, Jun Yan, Hong Zhang, Anthony Marotta and Zaihui Zhang
Title Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model
Journal
Vol
Issue
Date
URL https://mct.aacrjournals.org/content/17/1_Supplement/B148
Abstract Text Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
SLC-391 SLC391|SLC 391 AXL Inhibitor 27 SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon carcinoma not applicable SLC-391 + unspecified PD-1 antibody Preclinical Actionable In a preclinical study, treatment with SLC-391 combined with an anti-PD-1 antibody demonstrated synergy and increased overall survival rate in a syngeneic mouse model of colon carcinoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). detail...
Unknown unknown colon carcinoma not applicable SLC-391 Preclinical Actionable In a preclinical study, SLC-391 treatment did not inhibit proliferation of a colon carcinoma cell line in culture, however, inhibited tumor growth by 37% in a syngeneic mouse model (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). detail...